Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Jauch, SF; Riethdorf, S; Sprick, MR; Schütz, F; Schönfisch, B; Brucker, SY; Deutsch, TM; Nees, J; Saini, M; Becker, LM; Burwinkel, B; Sinn, P; Marmé, F; Pantel, K; Jäger, D; Sohn, C; Trumpp, A; Wallwiener, M; Schneeweiss, A.
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
Breast Cancer Res Treat. 2019; 173(1): 155-165. Doi: 10.1007/s10549-018-4972-y
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Jauch Sarah Francesca
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: PURPOSE: Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its prognostic value on progression-free survival and overall survival (OS) in patients with stage IV breast cancer. This study prospectively evaluated the role of CTCs as a prognostic marker during further progression of metastatic breast cancer (MBC). METHODS: Among 476 MBC patients recruited between 2010 and 2015, the 103 patients with a known CTC status at baseline (CTC_BL) and within 4 weeks of tumor progression (CTC_PD) were included. Progressive disease (PD) was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Using the CellSearch method, < 5 and ≥ 5 CTCs per 7.5 ml blood were determined as negative and positive, respectively. A shift in CTC status from baseline to progression ([Formula: see text] to [Formula: see text] and vice versa) was considered as alternating Kinetics_BL-PD. RESULTS: Median follow-up was 29.9 [21.2, 40.0] months. CTC_PD positivity (37%, n = 38) was associated with a significantly shorter OS than CTC_PD negativity (8.0 [5.1, 10.9] vs 22.6 [15.3, 39.8] months; P < 0.001). Alternating Kinetics_BL-PD was observed in 24% of the patients. This significantly changed the OS prediction of [Formula: see text] patients ([Formula: see text] vs [Formula: see text], 11.4 [9.7, not available (NA)] vs. 7.6 [4.4, 11.5] months; P = 0.044) and [Formula: see text] patients ([Formula: see text] vs. [Formula: see text], 8.4 [4.0, NA] vs. 22.6 [18.9, NA] months, respectively; P < 0.001). Prediction of survival was significantly improved (P = 0.002) by adding CTC_PD status to clinicopathological characteristics and CTC_BL status. CONCLUSIONS: CTC status upon further disease progression is a prognostic factor that could significantly improve well-established models. Thus, it represents a potential additional instrument supporting treatment decision.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Aged - administration & dosage; Aged, 80 and over - administration & dosage; Biomarkers, Tumor - administration & dosage; Breast Neoplasms - metabolism, mortality, pathology, therapy; Female - administration & dosage; Humans - administration & dosage; Middle Aged - administration & dosage; Neoplastic Cells, Circulating - pathology; Prognosis - administration & dosage; Prospective Studies - administration & dosage; Regression Analysis - administration & dosage
Find related publications in this database (Keywords): CTCs; Circulating tumor cells; Metastatic breast cancer; Progressive disease; Survival; Prognostic marker